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Background. There is concern about the rising prevalence
of type 2 diabetes mellitus and of the resultant nephropathy.
This study uses data from the European Renal Association-
European Dialysis and Transplant Association (ERA-EDTA)
Registry to provide information on the epidemiology and out-
come of renal replacement therapy (RRT) for end-stage renal
disease (ESRD) due to diabetic nephropathy (DN).
Methods. Data from the following 10 registries: Austria,
French-speaking Belgium, Denmark, Finland, Greece, Norway,
Scotland (UK), Catalonia (Spain), Sweden, and The Nether-
lands were combined. Average annual changes (%) were es-
timated by Poisson regression. Analyses of mortality were
performed by Cox regression.
Results. An increase in patients with type 2 DN entering RRT
has been observed (+11.9% annually, P < 0.05), while large dif-
ferences in RRT incidence in this disease continue to exist be-
tween countries in Europe. There was a reduction in mortality
during the first 2 years on dialysis therapy among patients with
type 2 DN (AHR 0.96, 95%CI 0.94–0.97 annually). The mortal-
ity among transplant recipients decreased for both type 1 DN
and nondiabetic ESRD (non DN) within the 1995–1998 cohort
(type 1 DN: AHR 0.49, 95% CI 0.35–0.68; non DN: AHR 0.79,
95% CI 0.69–0.90) compared to the 1991–1994 cohort.
Conclusion. This report has shown that during the last decade
there has been a marked increase in the incidence of RRT for
type 2 DN. Survival analysis showed that over the period 1991–
1999 the mortality rates of all dialysis patients and of type 1
diabetic and nondiabetic renal transplant recipients have fallen.
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In 1997, diabetes mellitus (DM) affected about 22
million people in Europe, and the number is expected
to rise to around the 33 million by 2010 [1]. Recent
studies found that diabetic patients are 12 to 17 times
more prone to develop renal disease as nondiabetic in-
dividuals [1, 2]. Also, publications have reported the
development of end-stage renal disease (ESRD) due
to diabetic nephropathy (DN) [2–4] after a mean in-
terval of 25 years in more than one third of patients
with insulin-dependent diabetes (IDDM), and in ap-
proximately 20% of those with non–insulin-dependent
diabetes (NIDDM) [3]. As a consequence of the contin-
uing increase of type 2 diabetes in the population, a fur-
ther rise in the incidence of diabetic ESRD is therefore
inevitable, and this will have a major impact on public
health.
Recent trends in the incidence and survival of dia-
betic ESRD have been well described for the United
States [5–7], but only crude data from individual coun-
tries were available for Europe. An increase in the in-
cidence of renal replacement therapy (RRT) due to
type 1 DN has been reported in Finland and Denmark
[8, 9], while a more substantial increase has been re-
ported for type 2 DN in several European countries
[8–13]. However, a more comprehensive overview of
the trends in epidemiology and outcome on both types
of diabetic ESRD from different parts of Europe was
lacking.
In this paper, we aim to provide an update of the sta-
tus of type 1 and type 2 diabetic ESRD in a number of
European countries, using standardized methods to com-
pare the incidence and prevalence of RRT, the treatment
modality, and patient outcome. To this end, we used data
from 10 national and regional registries which collab-
orate with the European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA)
Registry.
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METHODS
Data collection
The ERA-EDTA Registry currently collects data from
16 European national and regional registries. The details
of the methods of data collection and data processing
have been described elsewhere [14]. The criteria for the
inclusion of registry data in the present study were: (1)
the availability of data over the period 1991–2000, and
(2) the use of separate codes for type 1 and type 2 di-
abetic nephropathy. The following 10 registries fulfilled
these criteria: Austria, French-speaking Belgium, Den-
mark, Finland, Greece, Norway (separate codes since
1995), Scotland (UK), Catalonia (Spain), Sweden, and
The Netherlands. These registries reported at least 98%
of all patients treated for ESRD in their country or region.
From the registries of Limousin and Lorraine (France),
Germany, Valencia, and Basque country (Spain), and the
UK (England/Wales), we only have recent individual pa-
tient data or aggregated data. For these registries we only
reported incidence and prevalence rates.
Data analysis
In this manuscript, patients with either type 1 or type
2 DM as the primary cause of renal failure and who com-
menced RRT will be further referenced as type 1 or type
2 diabetic nephropathy (DN) patients. The date of onset
of ESRD was defined as the date of start of RRT. Pa-
tients with a diagnosis of acute renal failure, patients not
residing in the area covered by a contributing registry,
and patients with a missing start date were excluded.
The incidence of RRT, the access to transplantation,
and the outcome of these DN patients were compared
with a nondiabetic ESRD (non DN) group consisting of
all other ESRD patients. The incidence of RRT was de-
fined as the number of new cases per year, and the preva-
lence was defined as the number of patients alive and on
RRT on December 31. For both of these items of data, the
midyear population (June 30) was used as denominator
[15].
To evaluate trends over time and differences in inci-
dence between countries, we adjusted for age and gender,
using the mid-1995 European population as the reference
[15]. Average annual changes (%) in adjusted incidence
rates were estimated by Poisson regression.
The type of renal disease and causes of death were de-
fined according to the ERA-EDTA coding systems, and
categorized according to the ERA-EDTA categories [14].
Cardiac causes of death comprised the following groups
from the list of codes: myocardial ischemia/infarction,
heart failure, and cardiac arrest [14]. To assess the access
to renal transplantation, whether preemptive or while on
dialysis, we calculated the number of first transplants per
1000 prevalent dialysis patients in a given year.
Differences were considered statistically significant if
the two-sided P value was less than 0.05. Statistical analy-
sis of crude survival was performed by the Kaplan-Meier
method, and adjusted hazard ratios (AHR) of mortality
were determined using Cox regression modeling for time
to death. Proportional hazards assumptions have been
verified. The first day of dialysis was taken as the start-
ing point for the analysis of patient survival on dialysis.
The death of the patient was the event studied. Trans-
plantation and recovery of renal function were censored
observations. For the analysis of patient survival after
transplantation, we took the date of the first renal trans-
plant as the first day of follow-up. Death was the event,
whereas the follow-up time was censored at loss of follow-
up. The follow-up time of patients alive and on RRT on
December 31, 2000, was censored at that date. Two-year
mortality rates (100% minus percent survival) were cal-
culated from a Cox regression model with adjustment for
the age and gender distribution of incident patients in
1999. Competing risk models have been used to assess
2-year mortality rates by cause of death. More detailed
information about the methodology of survival analysis
is given elsewhere [14].
RESULTS
The study population consisted of 100,509 patients on
RRT from the 10 registries listed above. Of these patients,
7469 had type 1 DN and 9404 had type 2 DN, while a fur-
ther 240 patients had DN of unspecified type. Among pa-
tients with type 1 DN starting RRT, the mean age ranged
from 43 years in Finland to 56 years in Greece (P < 0.05).
The mean age of those with type 2 DN starting RRT var-
ied from 65 years in Norway to 68 years in the Spanish
region of Catalonia (P < 0.05). Overall, the mean age of
type 1 DN patients at the start of RRT rose from 49 years
in 1991 to 53 years in 2000 (P < 0.05). In patients with
type 2 DN it increased from 64 years in 1991 to 67 years
in 2000 (P < 0.05).
Crude incidence and prevalence rates
The crude incidence and prevalence rates of RRT for
ESRD due to DN or non DN are shown in Table 1 and
Table 2. Overall, there was an increase with time in the
incidence and prevalence of RRT in both type 1 and type
2 DN and non DN. In the countries where type 2 DN was
higher at baseline, the increase over the 10-year period
was higher (r = 0.74; P < 0.05). The ratio between type
2 and type 1 DN in the incidence of RRT was less than 1
at the beginning of the decade, and close to 2 by the end.
The upper panel of Figure 1 shows that the incidence
of RRT for type 1 DN was highest in the 45–64 year age
group, and higher in males than in females. There was
a statistically significant increase in males of 65 years of
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Table 1. Crude incidence and prevalence of RRT for diabetic and nondiabetic ESRD by country (PMP)
Incidence (95% CI) Prevalence (95% CI)
Type 1 DN Type 2 DN Non DN Type 1 DN Type 2 DN Non DN
All countriesa 1991–1992 7.7 (7.2–8.2) 7.1 (6.6–7.5) 67.8 (66.4–69.2) 35.8 (34.8–36.8) 15.7 (15.0–16.3) 455.8 (452.2–459.4)
1999–2000 9.0 (8.5–9.4) 17.9 (17.2–18.6) 93.8 (92.2–95.3) 50.3 (49.2–51.4) 44.5 (43.5–45.6) 607.2 (603.2–611.2)
Austria 1991–1992 9.6 (8.1–11.1) 15.7 (13.8–17.7) 74.6 (70.3–78.9) 36.8 (33.8–39.8) 31.9 (29.1–34.7) 511.6 (500.3–522.8)
1999–2000 8.3 (6.9–9.7) 34.1 (31.3–37.0) 89.7 (85.0–94.3) 46.4 (43.1–49.7) 81.3 (76.9–85.7) 584.7 (572.9–596.5)
Belgium, 1991–1992 7.1 (5.3–8.9) 5.7 (4.1–7.3) 68.7 (63.1–74.3) 25.7 (22.3–29.1) 14.0 (11.4–16.5) 437.8 (423.7–451.9)
French-speaking 1999–2000 3.8 (2.5–5.2) 31.1 (27.4–34.8) 120.1 (112.8–127.4) 28.4 (24.9–32.0) 75.8 (70.0–81.6) 670.1 (652.7–687.4)
Denmark 1991–1992 11.2 (9.2–13.3) 2.2 (1.3–3.1) 55.5 (51.0–60.0) 37.6 (33.8–41.3) 4.3 (3–5.5.0) 350.9 (339.5–362.3)
1999–2000 16.3 (13.9–18.8) 11.8 (9.8–13.9) 99.3 (93.3–105.2) 73.1 (68.0–78.2) 24.0 (21.1–27.0) 533.6 (519.7–547.4)
Finland 1991–1992 12.3 (10.2–14.5) 3.0 (1.9–4.1) 43.0 (38.9–47.0) 67.3 (62.3–72.4) 7.4 (5.7–9.0) 286.8 (276.3–297.3)
1999–2000 13.3 (11.1–15.6) 16.2 (13.8–18.7) 63.3 (58.5–68.2) 98.4 (92.4–104.5) 37.7 (34.0–41.5) 430.0 (417.4–442.6)
Greece 1991–1992 3.2 (2.4–4.0) 8.4 (7.1–9.6) 69.9 (66.3–73.5) 10.1 (8.7–11.5) 21.2 (19.3–23.2) 419.1 (410.2–427.9)
1999–2000 7.2 (6.0–8.3) 26.8 (24.6–29.0) 107.3 (102.8–111.7) 27.8 (25.6–30.1) 73.4 (69.7–77.0) 675.5 (664.4–686.6)
Norway 1991–1992 8.1 (1+2) (6.2–10.0) 55.6 (50.6–60.6) 39.1 (1+2) (34.9–43.3) 340.7 (328.3–353.0)
1999–2000 5.6 (4.0–7.1) 6.6 (4.9–8.3) 76.8 (71.1–82.6) 50.7 (1+2) (46.0–55.4) 518.3 (503.4–533.2)
Spain, Catalonia 1991–1992 3.5 (2.5–4.6) 12.5 (10.5–14.5) 84.3 (79.2–89.5) 22.1 (19.4–24.7) 30.2 (27.1–33.3) 709.6 (694.6–724.6)
1999–2000 6.2 (4.8–7.6) 22.4 (19.8–25.1) 119.3 (113.2–125.4) 47.6 (43.7–51.4) 70.3 (65.7–75.0) 951.5 (934.2–968.7)
Sweden 1991–1992 12.1 (10.5–13.8) 9.4 (7.9–10.8) 81.9 (77.6–86.1) 71.3 (67.3–75.3) 15.6 (13.7–17.4) 410.5 (400.9–420.0)
1999–2000 13.4 (11.7–15.1) 16.5 (14.6–18.4) 97.2 (92.6–101.8) 88.3 (83.9–92.6) 37.9 (35.0–40.8) 583.8 (572.6–595.1)
The Netherlands 1991–1992 6.3 (5.4–7.2) 3.1 (2.4–3.7) 64.1 (61.3–67.0) 22.4 (20.8–24.1) 8.4 (7.4–9.4) 407.0 (399.8–414.2)
1999–2000 6.3 (5.4–7.2) 8.4 (7.4–9.4) 81.6 (78.5–84.8) 30.2 (28.3–32.2) 22.9 (21.2–24.5) 562.0 (553.8–570.3)
UK, Scotland 1991–1992 7.4 (5.8–9.1) 2.5 (1.6–3.5) 56.7 (52.1–61.4) 25.0 (22.0–28.1) 5.0 (3.6–6.4) 366.5 (354.8–378.3)
1999–2000 12.7 (10.5–14.9) 7.1 (5.5–8.8) 91.1 (85.2–96.9) 48.1 (43.8–52.3) 15.8 (13.4–18.3) 549.1 (534.7–563.4)
aUntil 1994, the registry in Norway did not use separate codes for type 1 and type 2 diabetic ESRD. Therefore, data from this country are not included in the “All
countries” incidence figures of the period 1991–1992, and are not included in the “All countries” prevalence figures for both time periods.
age or older (P < 0.05). The lower panel shows that the
incidence of RRT for type 2 DN has increased markedly
with time in the 45–64 year age group, and to an even
greater extent in patients of 65 years of age or older. In
addition, it shows that in 1991 the male to female ratio in
the 65+ year age group was 1.3, while by 2000 it had risen
to 1.5, indicating a greater increase with time in males
than in females.
Adjusted incidence rates
Figure 2 shows the age- and gender-adjusted incidence
rates of RRT for type 1 and type 2 DN by country. The in-
cidence of RRT for type 1 DN (upper panel) was highest
in Denmark, Sweden, and Finland. There was a statisti-
cally significant increase in incidence with time in Greece
and Scotland (P < 0.001), and a decrease in French-
speaking Belgium. By contrast, the incidence of RRT
for type 2 DN was highest in Austria, French-speaking
Belgium, and Greece, and it increased markedly with
time in all countries, with a mean annual rise of 11.9%
(95%CI 10.5–13.4). The average annual change in type
2 DN varied from 6.5% (95%CI 2.7–10.5) in Sweden to
20.6% (95%CI 14.9–26.6) in French-speaking Belgium.
Modality at 3 months
At 3 months after the start of RRT, 58% of the pa-
tients with type 1 DN were on haemodialysis (HD), 38%
were on peritoneal dialysis (PD), and 4% had a func-
tioning transplant. Among patients with type 2 DN 81%
were on HD, and 19% on PD. Overall, the percentage
on hemodialysis in comparison with peritoneal dialy-
sis increased with age, but varied between countries. In
Norway, the percentage of patients living with a func-
tioning transplant at 3 months after the start of RRT was
higher than in any of the other countries (18% for type 1
DN and 4% for type 2 DN).
Access to transplantation
The transplant rates, when expressed as the number of
first transplants per 1000 prevalent dialysis patients, have
declined over the 10 years of the study (Fig. 3). Younger
(0–44 years) type 1 DN patients tended to have higher
transplant rates, and older (55–64 years) type 1 DN pa-
tients lower transplant rates compared to the non DN
group. We did not analyze the transplant rates of patients
with type 2 DN in the 0–44 year age category, as the num-
ber of patients and of transplants in this age group was too
low. In the 45–64 year age category, type 2 DN patients
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had lower transplant rates when compared to patients
with type 1 DN and to non DN patients. Although the
overall transplant rates differed across countries, similar
patterns by patient group (type 1, type 2, and non DN)
were observed between countries. Of all 10 countries, the
transplant rate was highest in Norway in both diabetic
and nondiabetic patients.
Mortality
Dialysis. The crude 1-, 2-, and 5-year dialysis patient
survival was, respectively, 81%, 62%, and 24% for type 1
DN, 75%, 56%, and 20% for type 2 DN, and 82%, 70%,
and 40% for non DN patients. Adjusted for age, gender,
and country, patients with type 1 and patients with type 2
DN had a higher mortality than non DN patients over the
10-year period (type 1 DN: AHR 2.00, 95%CI 1.92–2.08;
type 2 DN: AHR 1.52, 95%CI 1.47–1.57).
Figure 4 shows the change over the decade in the age-
and gender-adjusted mortality during the first 2 years of
dialysis therapy. There was a marked reduction among
patients with type 2 DN, while the reduction was more
modest in patients with type 1 DN and in non DN patients
(type 1 DN: AHR 0.99, 95%CI 0.97–1.00; type 2 DN:
AHR 0.96, 95%CI 0.94–0.97; non DN: AHR 0.99, 95%CI
0.98–1.00; for each year increase during the period 1991–
1999).
Transplantation. The crude 1-, 2-, and 5-year patient
survival after a first transplant was, respectively, 94%,
90%, and 79% for type 1 DN, 86%, 83%, and 61% for
type 2 DN patients, and 96%, 94%, and 87% for non
DN patients. The patient survival after a first transplant
adjusted for age, gender, donor type, and country was
lower in patients with DN than in non DN patients (type
1 DN: AHR 2.21, 95% CI 1.98–2.47; type 2 DN: AHR
2.02, 95% CI 1.68–2.43).
Figure 5 (upper panel) shows the age- and gender-
adjusted mortality in first transplant recipients with type 1
DN and in non DN patients, comparing the periods 1991–
1994 (reference) and 1995–1998. This analysis shows that
the mortality in both type 1 DN and in non DN trans-
plant recipients decreased, and that the reduction was
more pronounced in type 1 DN patients than in the non
DN group (type 1 DN: AHR 0.49, 95%CI 0.35–0.68; non
DN: AHR 0.79, 95%CI 0.69–0.90). In the lower panel of
Figure 5, the patients are divided into 4 age groups, show-
ing that in the more recent cohort (1995–1998) the ad-
justed 2-year mortality of transplant recipients with type
1 DN remained significantly higher than in the non DN
group (reference group, AHR = 1) for patients in the
0–34 and the 35–44 years age group (0–34 age group:
AHR 3.88, 95%CI 1.83–8.23; 35–44 age group: AHR 1.96,
95%CI 1.09–3.50), but not in the 45–54 and the 55–64
years age group (45–54 age group: AHR 1.61, 95%CI
0.96–2.70; 55–64 age group: AHR 1.81, 95%CI 0.91–3.60).
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Fig. 1. Trends in incidence of RRT for the treatment of type 1 (A) and type 2 (B) DN patients by gender and age category. The numbers on the
righthand side indicate the incidence per million age and gender related population for each group for the year 2000.
Cause of death
Figure 6 shows the mortality rate of DN and non DN
patients by age category. Both cardiac and noncardiac
mortality were higher in DN patients than in non DN
patients. The proportion of deaths attributable to cardiac
causes was approximately 40% in type 1 and in type 2
DN patients in all age categories. In non DN patients the
percentage of deaths due to cardiac causes in the 0 to
44 year age group was relatively low (22%), but it rose
with increasing age to come close to the figures for the 2
groups of DN patients.
We also investigated whether the reduction in mortal-
ity over the period of the study could be attributed to
any specific causes of death (Table 3). The data showed
that in type 1 DN and non DN dialysis patients, the re-
duction in 2-year mortality was almost entirely due to a
decrease in death from myocardial infarction and heart
failure. In patients with type 2 DN there was a similar
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Fig. 2. Age- and gender-adjusted incidence
of type 1 (A) and type 2 (B) DN (pmp) by
country and year. ∗P < 0.05 for the within
group trend (mean % annual change).
reduction in deaths from these 2 causes, but also an impor-
tant decrease in mortality from cerebrovascular accidents
(AHR 0.92, 95%CI 0.88–0.98 for each year increase dur-
ing the period 1991–1999). In transplant recipients, the
number of events was too small to analyze mortality by
specific causes of death, but we did find that over the pe-
riod of the study the reduction in mortality among type
1 DN patients was due to a decrease in both cardiac and
noncardiac causes of death (cardiac: AHR 0.53, 95%CI
0.29–0.96; noncardiac: AHR 0.46, 95%CI 0.30–0.68 pe-
riod 1991–1994 versus 1995–1998). In non DN patients
there was a statistically significant reduction in noncar-
diac mortality, but the decrease in cardiac mortality did
not reach statistical significance.
DISCUSSION
This report has shown that during the last decade there
has been a small rise in the incidence of RRT for type 1
DN, but a marked increase in that for type 2 DN. The small
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patients with diabetic ESRD versus nondi-
abetic ESRD (adjusted to the age, gender,
and country distribution of incident patients
in 1999).
increase in RRT incidence for type 1 DN is in line with
the approximately 2.4% annual increase in type 1 DM
prevalence which has taken place in the general popula-
tion during the last 3 decades in 5 of the countries partic-
ipating in this study [16]. It is not clear why in our study
the incidence of RRT for type 1 DN was found to have
fallen in French-speaking Belgium, whereas it increased
in most other European countries. In the United States,
however, the incidence of RRT for type 1 DN decreased
over the period 1994–2001, as well [5, 6].The increase in
RRT incidence for type 2 DN was considerable in all 10
countries, although the level of increase varied between
them. Reports of similar large increases have come from
other countries and regions [6, 8–10, 12, 17–20].
One concern when trying to interpret registry data in
this field is the scope for misclassification of primary renal
disease. There are 2 types of potential misclassification.
The first one is that between DN and non DN, and the
second type is that of misclassification between type 1
and type 2 DN. In the absence of a well-established inter-
national standard method for labeling nonbiopsy-proven
nephropathy in patients with DM, diagnoses are primar-
ily based on the opinion of the attending nephrologist.
Thus, misclassification may vary both between and within
countries, and we were not able to assess its magnitude
and direction. With regard to the type of diabetes we
had no information whether the diagnosis was based on
the opinion of a nephrologist or on a standard algorithm.
One French study reported that more than one third of
all type 2 diabetic patients had been wrongly classified by
nephrologists as patients with type 1 DN [21]. We would
consider misclassification of this degree in our contribut-
ing registries unlikely, but if a similar misclassification of
type 1 DN versus type 2 DN has occurred in our study, the
true number of patients with type 2 DN would be even
higher than we have recorded.
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Table 3. Cardiac mortality in dialysis patients and transplant recipients with diabetic and nondiabetic ESRD patients
Dialysis patientsa Transplant recipientsb
AHR 95%CI AHR 95%CI
Cardiac deathsc Type 1 DN 0.96 (0.93–0.99) 0.53 (0.29–0.96)
Type 2 DN 0.96 (0.94–0.98) NA
Non DN 0.98 (0.96–0.98) 0.86 (0.64–1.14)
Myocardial infarct/ischemia Type 1 DN 0.93 (0.89–0.98)
Type 2 DN 0.97 (0.93–1.01) NA
Non DN 0.94 (0.93–0.96)
Heart failure Type 1 DN 0.89 (0.83–0.96)
Type 2 DN 0.93 (0.88–0.97) NA
Non DN 0.94 (0.92–0.97)
Cardiac arrest Type 1 DN 1.03 (0.97–1.09) NA
Type 2 DN 0.97 (0.93–1.02)
Non DN 1.02 (1.00–1.04)
NA, not applicable because the number of cases was too low to calculate a confidence interval.
aAdjusted hazard ratio for the annual increase during the period 1991 to 1999, adjusted for age, gender, and country distribution of incident patients in 1999.
bAdjusted hazard ratio for cohort 1991 to 1994 (ref) versus 1995 to 1998, adjusted for age, gender, country, and donor type distribution of incident patients in 1999.
cThe group of cardiac deaths consists of the following causes of death: myocardial infarction and ischemia, heart failure, and cardiac arrest.
Potential explanations for the rise in the incidence of
RRT for type 2 DN are an increased prevalence of DM,
an improved life expectancy in patients with DM, and
greater access to dialysis therapy. One obvious question
is whether the increase in incidence of RRT for type 2
DN could in part be due to changes in the age and gen-
der distribution of the population. However, adjustment
for these 2 factors using figures for the European popu-
lation in 1995 has ruled out such changes as a significant
contributor to the increases observed in RRT incidence.
An alarming rise in the prevalence of type 2 DM in
Europe and indeed worldwide, has been shown in a
number of population-based studies [1, 22–24]. Increased
rates of obesity due to low levels of physical activity and
high-energy diets are believed to be driving this global
epidemic [25]. It should be noted, however, that the
prevalence may rise, even if the incidence and mortal-
ity remain stable for a longer period of time. This could
be the case when new cases outnumber the deaths among
the prevalent diabetic patients. Unfortunately, reliable in-
formation on the prevalence of type 2 DM in individual
European countries is lacking. A recent publication by
the DECODE study group [24], which included data on
diagnosed and undiagnosed diabetes from 4 of our 10 par-
ticipating countries, has shown that the total prevalence
of diabetes in the early 1990s was higher in Catalonia
than in Finland, Sweden, and The Netherlands, which is
in line with our data. An interesting study by Wimmer et
al showed that the geographical variation in the incidence
of RRT for type 2 DN within Austria paralleled the sales
of oral hypoglycaemic agents and the body mass index in
the general population [26]. This suggests that real geo-
graphical differences in the prevalence of diabetes in the
general population account to an important extent for
differences in the incidence of RRT for diabetic ESRD.
In the United States, a study during the time period 1978–
1991 tried to quantify the contribution of diabetes preva-
lence, and showed that the increase in diabetes in the
general population accounted for nearly 28% of the in-
crease in the incidence of RRT in general, and 60% of the
increase in RRT incidence for diabetic ESRD [27]. More-
over, this study showed that the improvement in survival
after a myocardial infarction or stroke was not a major
cause of the increase in RRT incidence among all cause
ESRD patients in the United States [27]. Another study
in a 95% white United States population showed that the
mortality of patients with DM declined by 13.8% during
the period 1970–1994 [28]. Also, a Danish study showed
a decrease in mortality in patients with drug-treated DM
and, although their data do not allow for a firm conclusion
as to why the prevalence of diabetes mellitus is rising, they
believe that the decrease in mortality should be taken
into account [29]. Therefore, it may be that a longer life
expectancy, together with increased success in the pre-
vention of MI and stroke, has resulted in more time at
risk for developing diabetic and nondiabetic ESRD. To
what extent the increase in RRT incidence for type 2 DN
is a result of wider access to dialysis therapy is difficult
to assess. A large multicenter study in The Netherlands
has shown that there was a time trend toward an earlier
start of dialysis during the period 1993–2000 [30], which
by itself would result in an increase of the incidence of
RRT.
Our analysis shows that the rate of transplantation is
falling because the increase in the demand for transplan-
tation is not being matched by a rise in the availabil-
ity of donor organs. Concern is often expressed that the
presence of comorbid disease, which is almost inevitable
in DM, and also in the older age groups, may lead to
reduced access to transplantation. In this context it is
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reassuring to note in our study that, in contrast to pa-
tients in the older age groups, those with type 1 DN in
the 0–44 year age group had a slightly higher transplant
rate when compared with nondiabetic ESRD patients of
similar age. Wolfe et al have shown that in the United
States, diabetic ESRD patients were markedly disadvan-
taged regarding wait-listing, but this publication did not
differentiate between type 1 and type 2 DN patients [31].
Our study is in line with other reports which have
shown that the survival of both diabetic and nondiabetic
dialysis patients has improved in the past 10 years [7],
suggesting an improvement in the management of these
patients. However, as we and others have shown, survival
among diabetic dialysis patients remains inferior to that
of the nondiabetic patient [17, 32, 33].
Turning to the outcome following renal transplanta-
tion, it is reassuring to see that not only has patient sur-
vival improved during the 1990s in all patients, which is in
agreement with reports from the USRDS [32], but also
there is a trend for the gap between survival in type 1
DN patients and in non DN patients to be narrowing. For
both the outcome on dialysis and following renal trans-
plantation, it should be noted that changes in diagnostic
criteria for initiation of RRT over time might have af-
fected the trend in survival. Unfortunately, we were not
able to adjust for this factor.
Cardiovascular disease is the most common cause of
death in ESRD patients. Also, Rodriguez et al [33] have
shown that diabetic nephropathy is the primary renal
disease that is associated with the largest number of
comorbid conditions within the ESRD population, that
these conditions are mainly vascular in nature, and that
their number increases considerably during the course
of RRT. This increased cardiovascular comorbidity re-
sults in more cardiac deaths in diabetic patients com-
pared with nondiabetic patients, as we have shown in this
study.
CONCLUSION
This analysis has highlighted the rapid rate of increase
in the number of patients with type 2 DN entering RRT,
and there is little doubt that this rapid increase will con-
tinue, with the resultant need for a considerable expan-
sion in dialysis resources. The large differences between
countries both in RRT incidence for type 2 DN patients
and the rate of increase in incidence merit further study.
There is also considerable scope for applying the knowl-
edge that has been acquired recently from study of the
mechanisms of progression to ESRD with the aim of
slowing the rate of deterioration in renal function. Also,
it is likely that the longer life expectancy that diabetic
patients in the general population now experience will
result in more time at risk for developing ESRD, and this
will also contribute to the increasing number of diabetic
patients starting RRT.
Finally, it is encouraging that the survival of patients
with diabetic ESRD both on dialysis and after a first trans-
plant is improving. Also, in patients with type 2 DN on
dialysis there has been a reduction in mortality due to
myocardial infarction, heart failure, and cerebrovascular
accidents. In the setting of the improving survival of the
diabetic following renal transplantation, it is disappoint-
ing that the deficit between supply and demand for donor
kidneys continues to grow.
ACKNOWLEDGMENTS
We would like to thank the patients and staff of all the dialysis and
transplant units who have contributed data via their national and re-
gional renal registries.
We also would like to thank the following registries for the contribu-
tion of these data: Austrian Dialysis and Transplant Registry (OEDTR),
General Hospital of Wels, Wels, Austria (Dr. R. Kramar and Dr. H.K.
Stumvoll); Basque Renal Registry, Grupo ALBOR-COHS, Cruces-
Baracaldo, Spain (Dr. O. Landeta); French-Belgian Nephrologists Reg-
istry, Center Hospitalier Etterbeek-Ixelles, Brussels, Belgium (Dr. F.
Collart); Registry of Renal Patients (RMRC), Catalan Transplant Orga-
nization (OCATT), Barcelona, Spain (Dr. M. Cle`ries and Mr. E. Vela);
Danish National Registry (Dr. H. Løkkegaard); Finnish Kidney Disease
Registry and Department of Medicine, Helsinki University Hospital,
Helsinki, Finland (Dr. C. Gro¨nhagen-Riska and Dr. P. Finne); Greek
national registry, General Hospital of Athens G. Gennimatas, Athens,
Greece (Dr. G.A. Ioannidis and Dr. N. Papagalanis); Dutch End-Stage
Renal Disease Registry (RENINE), Erasmus University Hospital,
Rotterdam, The Netherlands (Dr. F. Th. de Charro); Norwegian Renal
Registry, Institute of Immunology, Rikshospitalet University Hospi-
tal, Oslo, Norway (Dr. T. Leivestad); Scottish Renal Registry, Glasgow
Royal Infirmary, Glasgow, Scotland, UK (Dr. K. Simpson); Swedish
Registry for Active treatment of Uremia, Sko¨vde, Sweden (Dr. J.
Ahlme´n and Dr. S. Scho¨n); UK Renal Registry, Southmead Hospital,
Bristol, England (Dr. D. Ansell); Valencian Renal Registry, Generalitat
Conselleria de Sanitat, Valencia, Spain (Dr. O. Zurriaga); and the other
ERA-EDTA Registry committee members and ERA-EDTA Registry
staff members for their advice in the analysis and the drafting of this pa-
per: Dr. G. Colasanti, Ir. R. Cornet, Dr. F.W. Dekker, Dr. H.J. Schober-
Halstenberg, Dr. K. Simpson, Dr. D. Tsakiris.
The ERA-EDTA Registry is funded by the European Renal Associ-
ation (ERA-EDTA). The following companies have committed funds
in the form of unrestricted educational grants to assist the ERA-EDTA
in the financial support of the Registry: Amgen, Baxter, Fresenius Med-
ical Care, Gambro, Hoffmann-La Roche, Ortho-Biotech, and Shire.
Reprint requests to Paul C.W. Van Dijk, MSc, ERA-EDTA Registry,
Academic Medical Center-University of Amsterdam, Dept. of Medi-
cal Informatics, J1B-113-1, P.O. Box 22700, 1100 DE Amsterdam, The
Netherlands.
E-mail: erareg@amc.uva.nl
REFERENCES
1. AMOS AF, MCCARTY DJ, ZIMMET P: The rising global burden of
diabetes and its complications: Estimates and projections to the
year 2010. Diabet Med 14:1–85, 1997
2. BRANCATI FL, WHELTON PK, RANDALL BL, et al: Risk of end-stage
renal disease in diabetes mellitus: A prospective cohort study of
men screened for MRFIT. Multiple Risk Factor Intervention Trial.
JAMA 278:2069–2074, 1997
3. WORLD HEALTH ORGANIZATION: Prevention of Diabetes Mellitus,
Geneva, Switzerland, World Health Organization, 1994
Van Dijk et al: RRT for diabetic ESRD: Data from 10 European registries 1499
4. NELSON GN: Kidney Diseases in Diabetes, Phoenix, NIDDK, 1995,
pp 349–400
5. USRDS: US Renal Data System 2000 Annual Data Report, 2000
6. USRDS: US Renal Data System 2003 Annual Data Report, 2003
7. WOLFE RA, PORT FK: Good news, bad news for diabetic versus non-
diabetic end-stage renal disease: Incidence and mortality [editorial].
Asaio J 45:117–118, 1999
8. FINNISH REGISTRY FOR KIDNEY DISEASES: Finnish Registry for Kidney
Diseases 1999 Annual Report, 1999
9. DANISH REGISTRY FOR KIDNEY DISEASE (DNS): Danish National
Registry Report on Dialysis and Transplantation in Denmark 2002,
Herlev, 2002
10. PEREZ GARCIA R, RODRIGUEZ BENITEZ P, DALL’ANESSE C, et al: Pre-
occupying increase in diabetes as cause for terminal kidney fail-
ure. Evaluation of treatment strategies. An Med Interna 18:175–180,
2001
11. RITZ E, RYCHLIK I, LOCATELLI F, et al: End-stage renal failure in type
2 diabetes: A medical catastrophe of worldwide dimensions. Am J
Kidney Dis 34:795–808, 1999
12. BERGREM H, LEIVESTAD T: Diabetic nephropathy and end-stage re-
nal failure: The Norwegian story. Adv Ren Replace Ther 8:4–12,
2001
13. STENGEL B, BILLON S, VAN DIJK PC, et al: Trends in the incidence of
renal replacement therapy for end-stage renal disease in Europe,
1990–1999. Nephrol Dial Transplant 18:1824–1833, 2003
14. VAN DIJK PC, JAGER KJ, DE CHARRO F, et al: Renal replacement
therapy in Europe: The results of a collaborative effort by the ERA-
EDTA registry and six national or regional registries. Nephrol Dial
Transplant 16:1120–1129, 2001
15. EUROSTAT: European Population Statistics 1990–2000, Luxembourg,
Eurostat Statistics Office, 2000
16. ONKAMO P, VAANANEN S, KARVONEN M, et al: Worldwide increase in
incidence of Type I diabetes—The analysis of the data on published
incidence trends. Diabetologia 42:1395–1403, 1999
17. CANADIAN ORGAN REPLACEMENT REGISTER: Canadian Organ Re-
placement Register 2001 Annual Data Report (Vol 1), 2001
18. AUSTRALIA AND NEW ZEALAND DIALYSIS AND TRANSPLANT REGISTRY:
Australia and New Zealand Dialysis and Transplant Registry Report
1998, 1998
19. HALIMI S, ZMIROU D, BENHAMOU PY, et al: Huge progression of dia-
betes prevalence and incidence among dialysed patients in mainland
France and overseas French territories. A second national survey six
years apart. (UREMIDIAB 2 study). Diabetes Metab 25:507–512,
1999
20. LIPPERT J, RITZ E, SCHWARZBECK A, et al: The rising tide of endstage
renal failure from diabetic nephropathy type II—An epidemiolog-
ical analysis [see comments]. Nephrol Dial Transplant 10:462–467,
1995
21. ZMIROU D, BENHAMOU PY, CORDONNIER D, et al: Diabetes melli-
tus prevalence among dialysed patients in France (UREMIDIAB
study). Nephrol Dial Transplant 7:1092–1097, 1992
22. KING H, AUBERT RE, HERMAN WH: Global burden of diabetes,
1995–2025: Prevalence, numerical estimates, and projections. Di-
abetes Care 21:1414–1431, 1998
23. PASSA P: Diabetes trends in Europe. Diabetes Metab Res Rev
18(Suppl 3):3–8, 2002
24. DECODE STUDY GROUP: Age- and sex-specific prevalences of di-
abetes and impaired glucose regulation in 13 European cohorts.
Diabetes Care 26:61–69, 2003
25. ZIMMET P, ALBERTI KGMM, SHAW J: Global and societal
implications of the diabetes epidemic. Nature 414:782–787,
2001
26. WIMMER F, OBERAIGNER W, KRAMAR R, et al: Regional variability
in the incidence of end-stage renal disease: An epidemiological ap-
proach. Nephrol Dial Transplant 18:1562–1567, 2003
27. MUNTNER P, CORESH J, POWE NR, et al: The contribution of increased
diabetes prevalence and improved myocardial infarction and stroke
survival to the increase in treated end-stage renal disease. J Am Soc
Nephrol 14:1568–1577, 2003
28. THOMAS RJ, PALUMBO PJ, MELTON LJ III, et al: Trends in the mor-
tality burden associated with diabetes mellitus: A population-based
study in Rochester, Minn, 1970–1994. Arch Intern Med 163:445–451,
2003
29. STOVRING H, ANDERSEN M, BECK-NIELSEN H, et al: Rising prevalence
of diabetes: Evidence from a Danish pharmaco-epidemiological
database. Lancet 362:537–538, 2003
30. TERMORSHUIZEN F, KOREVAAR JC, DEKKER FW, et al: Time trends
in initiation and dose of dialysis in end-stage renal disease pa-
tients in The Netherlands. Nephrol Dial Transplant 18:552–558,
2003
31. WOLFE RA, ASHBY VB, MILFORD EL, et al: Differences in access to
cadaveric renal transplantation in the United States. Am J Kidney
Dis 36:1025–1033, 2000
32. USRDS: US Renal Data System 2001 Annual Data Report, 2001
33. RODRIGUEZ JA, CLERIES M, VELA E: Diabetic patients on re-
nal replacement therapy: Analysis of Catalan Registry data. Re-
nal Registry Committee. Nephrol Dial Transplant 12:2501–2509,
1997
